Pfizer Opens Cambridge R&D Center To Foster Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma plays up its ability to work with external partners weeks after its attempted acquisition of AstraZeneca fell through. The new facility is part of its plan to increase ties between scientists.